Announced

Completed

Coloplast completed the acquisition of Kerecis for $1.3bn.

Synopsis

Coloplast, a manufacturer of medical devices, completed the acquisition of Kerecis, a biotechnology company pioneering the use of fish skin, for $1.3bn. “I am very excited to welcome the Kerecis team into the Coloplast family. Both Coloplast and Kerecis are on a mission to help many more patients in need of advanced wound treatment, and I look forward to continuing the growth and profitability journey, as we build a truly global wound care franchise together,” Kristian Villumsen, Coloplast President and CEO.

Principals

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US